\-\ Texto\\:\\ \ \(0\)\
\-\ hypoxic\\,\\ tachypneic\\,\\ fatigued\\ black\\ female\\ with\\ diffuse\\ crackles\\.\\ \\ cd4\\ count\\ of\\ 6\\.\ \(0\)\
\-\ the\\ patient\\â\\€\\™s\\ respiratory\\ status\\ continued\\ to\\ worsen\\ during\\ her\\ first\\ 48\\ hours\\ of\\ admission\\.\\ \\ she\\ subsequently\\ required\\ intubation\\ for\\ 5\\ days\\.\\ \\ her\\ inpatient\\ course\\ was\\ complicated\\ by\\ a\\ moderate\\ right\\-sided\\ pneumothorax\\.\\ \\ her\\ respiratory\\ symptoms\\ eventually\\ improved\\ and\\ she\\ was\\ discharged\\ to\\ home\\.\ \(0\)\
\-\ summary\\ of\\ image\\ findings\\:\\ \ \(0\)\
\-\ cxr\\:\\ \\ \ \(0\)\
\-\ unremarkable\\ chest\\ radiograph\\ obtained\\ at\\ admission\\.\ \(0\)\
\-\ frontal\\ chest\\ radiograph\\ taken\\ 48\\ hours\\ after\\ admission\\ demonstrating\\ ill\\-defined\\ ground\\ glass\\ opacities\\ within\\ the\\ bilateral\\ suprahilar\\ regions\\.\\ \\ there\\ is\\ also\\ a\\ retrocardiac\\ opacity\\.\\ \\ atypical\\ or\\ viral\\ infectious\\ process\\.\\ \\ a\\ ct\\ was\\ recommended\\.\\ \\ the\\ admission\\ chest\\ x\\-ray\\ was\\ unremarkable\\.\\ \\ \ \(0\)\
\-\ frontal\\ chest\\ radiograph\\ taken\\ at\\ 72hrs\\ demonstrates\\ interval\\ placement\\ of\\ endotracheal\\ tube\\ and\\ right\\-sided\\ central\\ venous\\ catheter\\.\\ \\ new\\ right\\-sided\\ subcutaneous\\ air\\.\\ \\ hypoinflation\\ and\\ mils\\ increased\\ interstitial\\ markings\\ of\\ the\\ lungs\\.\\ \\ \ \(0\)\
\-\ portable\\ chest\\ radiograph\\ demonstrates\\ interval\\ development\\ of\\ moderate\\ right\\-sided\\ pneumothorax\ \(0\)\
\-\ ct\\:\ \(17\)\
\-\ chest\\ ct\\ demonstrating\\ diffuse\\ patchy\\ bilateral\\ upper\\ and\\ lower\\ lobe\\ groundglass\\ opacities\\.\\ \\ differential\\ considerations\\ include\\ pcp\\ and\\ cmv\\ pneumonia\\ as\\ well\\ as\\ other\\ opportunistic\\ infection\\.\\ \\ this\\ could\\ represent\\ hypersensitivity\\ pneumonitis\\.\ \(0\)\
\-\ pcp\\ pneumonia\\ \\(pneumocystis\\ jiroveci\\ pneumonia\\)\ \(0\)\
\-\ non\\-cardiogenic\\ edema\ \(0\)\
\-\ cytomegalovirus\\ pneumonitis\ \(0\)\
\-\ diffuse\\ pulmonary\\ hemorrhage\\ syndromes\ \(0\)\
\-\ hypersensitivity\\ pneumonitis\ \(9\)\
\-\ pulmonary\\ alveolar\\ proteinosis\ \(1\)\
\-\ 31y\\/o\\ black\\ female\\ who\\ is\\ hiv\\ positive\\,\\ with\\ slow\\ onset\\ of\\ fatigue\\,\\ low\\ grade\\ fever\\ and\\ dyspnea\\ over\\ the\\ past\\ several\\ weeks\\.\ \(0\)\
\-\ pneumocystis\\ pneumonia\\ \\(pcp\\)\\ is\\ a\\ potentially\\ life\\-threatening\\ infection\\ that\\ occurs\\ primarily\\ in\\ immunocompromised\\ individuals\\.\\ the\\ nomenclature\\ for\\ the\\ species\\ of\\ pneumocystis\\ that\\ infects\\ humans\\ has\\ been\\ changed\\ from\\ pneumocystis\\ carinii\\ to\\ pneumocystis\\ jirovecii\\.\\ \\ typical\\ immunocompromised\\ states\\ include\\ aids\\ patients\\ with\\ cd4\\ counts\\<200\\,\\ long\\ term\\ corticosteroid\\ therapy\\,\\ organ\\ transplants\\,\\ and\\ chemotherapy\\ patients\\.\\ \\ \ \(0\)\
\-\ in\\ immunocompetent\\ patients\\ presenting\\ symptoms\\ develop\\ rapidly\\ \\(over\\ 4\\-10\\ days\\)\\;\\ and\\ include\\ hypoxia\\,\\ dry\\ cough\\,\\ and\\ fever\\.\\ \\ a\\ less\\ specific\\,\\ indolent\\ pattern\\ \\(over\\ 2\\-6\\ weeks\\)\\ is\\ more\\ common\\ in\\ immunocompromised\\ patients\\;\\ including\\ fever\\,\\ malaise\\,\\ and\\ dyspnea\\.\\ \\ \\ \\ \ \(0\)\
\-\ clinical\\ suspicion\\ should\\ be\\ high\\ in\\ a\\ hypoxic\\,\\ immunocompromised\\ patient\\ with\\ ground\\-glass\\ opacities\\ on\\ plain\\ film\\ or\\ high\\-resolution\\ ct\\.\ \(0\)\
\-\ cxr\\:\\ perihilar\\ or\\ diffuse\\ ground\\-glass\\ opacities\\ early\\,\\ which\\ can\\ advance\\ to\\ a\\ consolidative\\ appearance\\ if\\ untreated\\.\\ \\ there\\ is\\ a\\ slight\\ upper\\ lobe\\ predominance\\,\\ which\\ may\\ be\\ associated\\ with\\ prophylaxis\\ with\\ aerosolized\\ pentamidine\\.\\ \\ upper\\ lobe\\ thin\\-walled\\ cysts\\ can\\ develop\\ in\\ 30\\%\\ of\\ aids\\ patients\\,\\ which\\ can\\ result\\ in\\ pneumothorax\\.\\ \\ \ \(0\)\
\-\ uncommon\\ plain\\ film\\ findings\\ include\\ multiple\\ pulmonary\\ nodules\\ \\(some\\ of\\ which\\ may\\ cavitate\\)\\,\\ a\\ miliary\\ pattern\\,\\ reticular\\ opacities\\,\\ and\\ asymmetric\\ consolidation\\.\ \(0\)\
\-\ pleural\\ effusions\\ and\\ enlarged\\ lymph\\ nodes\\ are\\ associated\\ rarely\\.\ \(0\)\
\-\ ct\\:\\ \\ ground\\ glass\\ opacities\\ on\\ hrct\\ are\\ the\\ predominant\\ finding\\.\\ \\ superimposed\\ smooth\\ intralobular\\ and\\ interlobular\\ septal\\ thickening\\ can\\ also\\ be\\ seen\\ \\(\\â\\€\\œcrazy\\-paving\\â\\€\\\\)\\.\\ \\ upper\\ lobe\\ cysts\\ can\\ be\\ demonstrated\\ more\\ frequently\\ on\\ ct\\.\\ \\ the\\ tree\\-in\\-bud\\ pattern\\ is\\ not\\ seen\\ in\\ association\\ with\\ pneumocystis\\ pneumonia\\.\\ \\ \ \(0\)\
\-\ references\\:\ \(0\)\
\-\ bollee\\,\\ g\\,\\ sarfati\\,\\ c\\,\\ thiery\\,\\ g\\,\\ et\\ al\\.\\ clinical\\ picture\\ of\\ pneumocystis\\ jirovecii\\ pneumonia\\ in\\ cancer\\ patients\\.\\ chest\\ 2007\\;\\ 132\\:1305\\.\ \(0\)\
\-\ gurney\\,\\ jw\\.\\ \\ diagnostic\\ imaging\\:\\ chest\\.\\ \\ salt\\ lake\\:\\ amirsus\\,\\ 2006\\.\\.\ \(0\)\
\-\ thomas\\,\\ cf\\,\\ jr\\.\\,\\ limper\\,\\ ah\\.\\ pneumocystis\\ pneumonia\\.\\ n\\ engl\\ j\\ med\\ 2004\\;\\ 350\\:2487\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pneumocystis\\:\\ 0\\.3782973750731634\ \(0\)\
\-\ opacities\\:\\ 0\\.21531306071860418\ \(0\)\
\-\ pneumonia\\:\\ 0\\.20766916193824383\ \(0\)\
\-\ immunocompromised\\:\\ 0\\.18562929754102842\ \(0\)\
\-\ chest\\:\\ 0\\.1587202402313423\ \(0\)\
\-\ glass\\:\\ 0\\.15123571124289734\ \(0\)\
\-\ ground\\:\\ 0\\.1463560465129562\ \(0\)\
\-\ pneumonitis\\:\\ 0\\.1304001242261073\ \(0\)\
\-\ patients\\:\\ 0\\.12686658356508063\ \(0\)\
\-\ pcp\\:\\ 0\\.12614797335090644\ \(0\)\
\-\ admission\\:\\ 0\\.1254406053271606\ \(0\)\
\-\ jirovecii\\:\\ 0\\.11487453969695006\ \(0\)\
\-\ and\\:\\ 0\\.10096812144333278\ \(0\)\
\-\ can\\:\\ 0\\.09862087644798648\ \(0\)\
\-\ pneumothorax\\:\\ 0\\.09827226229824394\ \(0\)\
\-\ radiograph\\:\\ 0\\.09792272721025405\ \(0\)\
\-\ cd4\\:\\ 0\\.09660576255951582\ \(0\)\
\-\ diffuse\\:\\ 0\\.09428541185385723\ \(0\)\
\-\ include\\:\\ 0\\.08945436892467382\ \(0\)\
\-\ hypersensitivity\\:\\ 0\\.08693341615073821\ \(0\)\
\-\ lobe\\:\\ 0\\.08688397275468535\ \(0\)\
\-\ hypoxic\\:\\ 0\\.08641656021605078\ \(0\)\
\-\ ct\\:\\ 0\\.0858570737202833\ \(0\)\
\-\ pattern\\:\\ 0\\.08418534159711295\ \(0\)\
\-\ in\\:\\ 0\\.08415258785746393\ \(0\)\
\-\ aids\\:\\ 0\\.08176703177311669\ \(0\)\
\-\ of\\:\\ 0\\.0809105089064057\ \(0\)\
\-\ upper\\:\\ 0\\.08034245521599125\ \(0\)\
\-\ black\\:\\ 0\\.07703115192269963\ \(0\)\
\-\ fever\\:\\ 0\\.076452273815968\ \(0\)\
\-\ her\\:\\ 0\\.07044563490264533\ \(0\)\
\-\ develop\\:\\ 0\\.06920259685336447\ \(0\)\
\-\ pulmonary\\:\\ 0\\.06873201199085155\ \(0\)\
\-\ which\\:\\ 0\\.06836372100170136\ \(0\)\
\-\ interval\\:\\ 0\\.0680216755412531\ \(0\)\
\-\ the\\:\\ 0\\.06749871836775002\ \(0\)\
\-\ dyspnea\\:\\ 0\\.06615261778230451\ \(0\)\
\-\ 48\\:\\ 0\\.06510618438118695\ \(0\)\
\-\ over\\:\\ 0\\.06269914672081967\ \(0\)\
\-\ demonstrating\\:\\ 0\\.06198572716984933\ \(0\)\
\-\ is\\:\\ 0\\.06175981902038807\ \(0\)\
\-\ be\\:\\ 0\\.06098927152604028\ \(0\)\
\-\ cxr\\:\\ 0\\.06013702377830538\ \(0\)\
\-\ 72hrs\\:\\ 0\\.06010890723833278\ \(0\)\
\-\ mils\\:\\ 0\\.06010890723833278\ \(0\)\
\-\ cavitate\\:\\ 0\\.06010890723833278\ \(0\)\
\-\ bollee\\:\\ 0\\.06010890723833278\ \(0\)\
\-\ sarfati\\:\\ 0\\.06010890723833278\ \(0\)\
\-\ thiery\\:\\ 0\\.06010890723833278\ \(0\)\
\-\ amirsus\\:\\ 0\\.06010890723833278\ \(0\)\
\-\ limper\\:\\ 0\\.06010890723833278\ \(0\)\
\-\ taken\\:\\ 0\\.06006820828464734\ \(0\)\
\-\ respiratory\\:\\ 0\\.059796484491199016\ \(0\)\
\-\ fatigued\\:\\ 0\\.05743726984847503\ \(0\)\
\-\ suprahilar\\:\\ 0\\.05743726984847503\ \(0\)\
\-\ infects\\:\\ 0\\.05743726984847503\ \(0\)\
\-\ aerosolized\\:\\ 0\\.05743726984847503\ \(0\)\
\-\ pentamidine\\:\\ 0\\.05743726984847503\ \(0\)\
\-\ gurney\\:\\ 0\\.05743726984847503\ \(0\)\
\-\ hours\\:\\ 0\\.057293356891102085\ \(0\)\
\-\ cysts\\:\\ 0\\.05696388630321956\ \(0\)\
\-\ moderate\\:\\ 0\\.056432437792552775\ \(0\)\
\-\ film\\:\\ 0\\.056174540382049505\ \(0\)\
\-\ hypoinflation\\:\\ 0\\.05554171295397422\ \(0\)\
\-\ groundglass\\:\\ 0\\.05554171295397422\ \(0\)\
\-\ humans\\:\\ 0\\.05554171295397422\ \(0\)\
\-\ jw\\:\\ 0\\.05554171295397422\ \(0\)\
\-\ lake\\:\\ 0\\.05554171295397422\ \(0\)\
\-\ ah\\:\\ 0\\.05554171295397422\ \(0\)\
\-\ opportunistic\\:\\ 0\\.05407140479903023\ \(0\)\
\-\ nomenclature\\:\\ 0\\.05407140479903023\ \(0\)\
\-\ immunocompetent\\:\\ 0\\.05287007556411647\ \(0\)\
\-\ indolent\\:\\ 0\\.05287007556411647\ \(0\)\
\-\ intralobular\\:\\ 0\\.05287007556411647\ \(0\)\
\-\ was\\:\\ 0\\.052396992030141\ \(0\)\
\-\ jiroveci\\:\\ 0\\.05185436616850399\ \(0\)\
\-\ thomas\\:\\ 0\\.05185436616850399\ \(0\)\
\-\ with\\:\\ 0\\.051519270037580146\ \(0\)\
\-\ engl\\:\\ 0\\.050974518669615665\ \(0\)\
\-\ unremarkable\\:\\ 0\\.05039586187586973\ \(0\)\
\-\ proteinosis\\:\\ 0\\.05019843817425872\ \(0\)\
\-\ transplants\\:\\ 0\\.05019843817425872\ \(0\)\
\-\ consolidative\\:\\ 0\\.05019843817425872\ \(0\)\
\-\ plain\\:\\ 0\\.04959694229856511\ \(0\)\
\-\ tachypneic\\:\\ 0\\.049504210514671666\ \(0\)\
\-\ species\\:\\ 0\\.049504210514671666\ \(0\)\
\-\ carinii\\:\\ 0\\.049504210514671666\ \(0\)\
\-\ advance\\:\\ 0\\.049504210514671666\ \(0\)\
\-\ salt\\:\\ 0\\.049504210514671666\ \(0\)\
\-\ cf\\:\\ 0\\.049504210514671666\ \(0\)\
\-\ cytomegalovirus\\:\\ 0\\.0488762052069218\ \(0\)\
\-\ miliary\\:\\ 0\\.0488762052069218\ \(0\)\
\-\ hrct\\:\\ 0\\.0488762052069218\ \(0\)\
\-\ frontal\\:\\ 0\\.04838328245467196\ \(0\)\
\-\ clinical\\:\\ 0\\.04764104312427128\ \(0\)\
\-\ days\\:\\ 0\\.047587690269656105\ \(0\)\
\-\ worsen\\:\\ 0\\.047287171884145426\ \(0\)\
\-\ counts\\:\\ 0\\.04683257312481391\ \(0\)\
\-\ interlobular\\:\\ 0\\.04683257312481391\ \(0\)\
\-\ summary\\:\\ 0\\.046007864596604796\ \(0\)\
\-\ infection\\:\\ 0\\.04540877464623322\ \(0\)\
\-\ retrocardiac\\:\\ 0\\.04527499126292233\ \(0\)\
\-\ weeks\\:\\ 0\\.04505258709615422\ \(0\)\
\-\ she\\:\\ 0\\.04474862976745957\ \(0\)\
\-\ endotracheal\\:\\ 0\\.04461553449428767\ \(0\)\
\-\ perihilar\\:\\ 0\\.044309010922563244\ \(0\)\
\-\ untreated\\:\\ 0\\.043466708075369107\ \(0\)\
\-\ reticular\\:\\ 0\\.04295960650004241\ \(0\)\
\-\ high\\:\\ 0\\.042723344621721004\ \(0\)\
\-\ corticosteroid\\:\\ 0\\.042488758488222186\ \(0\)\
\-\ superimposed\\:\\ 0\\.042488758488222186\ \(0\)\
\-\ predominant\\:\\ 0\\.04226537884045535\ \(0\)\
\-\ intubation\\:\\ 0\\.04204932445030215\ \(0\)\
\-\ cmv\\:\\ 0\\.04204932445030215\ \(0\)\
\-\ changed\\:\\ 0\\.04204932445030215\ \(0\)\
\-\ malaise\\:\\ 0\\.04163737353270548\ \(0\)\
\-\ predominance\\:\\ 0\\.04163737353270548\ \(0\)\
\-\ 200\\:\\ 0\\.041440670312246235\ \(0\)\
\-\ hypoxia\\:\\ 0\\.041440670312246235\ \(0\)\
\-\ prophylaxis\\:\\ 0\\.041440670312246235\ \(0\)\
\-\ more\\:\\ 0\\.04127795628252183\ \(0\)\
\-\ symptoms\\:\\ 0\\.041130346483082274\ \(0\)\
\-\ bilateral\\:\\ 0\\.04040068442799262\ \(0\)\
\-\ inpatient\\:\\ 0\\.040369821945954544\ \(0\)\
\-\ portable\\:\\ 0\\.03989329614959962\ \(0\)\
\-\ associated\\:\\ 0\\.03962174962159412\ \(0\)\
\-\ dry\\:\\ 0\\.039593741450597596\ \(0\)\
\-\ alveolar\\:\\ 0\\.03944892092768737\ \(0\)\
\-\ potentially\\:\\ 0\\.03944892092768737\ \(0\)\
\-\ picture\\:\\ 0\\.03944892092768737\ \(0\)\
\-\ individuals\\:\\ 0\\.03930721506734746\ \(0\)\
\-\ or\\:\\ 0\\.03922696421723898\ \(0\)\
\-\ considerations\\:\\ 0\\.038899513791010545\ \(0\)\
\-\ crackles\\:\\ 0\\.03876903292238848\ \(0\)\
\-\ syndromes\\:\\ 0\\.03864108582366683\ \(0\)\
\-\ organ\\:\\ 0\\.03864108582366683\ \(0\)\
\-\ may\\:\\ 0\\.03782936803304643\ \(0\)\
\-\ med\\:\\ 0\\.037808927810724334\ \(0\)\
\-\ demonstrates\\:\\ 0\\.03776604192805593\ \(0\)\
\-\ markings\\:\\ 0\\.03769818455609679\ \(0\)\
\-\ rapidly\\:\\ 0\\.03758927185254223\ \(0\)\
\-\ to\\:\\ 0\\.0375861491069336\ \(0\)\
\-\ eventually\\:\\ 0\\.03748213016594359\ \(0\)\
\-\ 2006\\:\\ 0\\.03748213016594359\ \(0\)\
\-\ hiv\\:\\ 0\\.03717077766872283\ \(0\)\
\-\ 2007\\:\\ 0\\.03717077766872283\ \(0\)\
\-\ findings\\:\\ 0\\.0371008358545375\ \(0\)\
\-\ patchy\\:\\ 0\\.03658901162823905\ \(0\)\
\-\ septal\\:\\ 0\\.03658901162823905\ \(0\)\
\-\ fatigue\\:\\ 0\\.036405970176192286\ \(0\)\
\-\ female\\:\\ 0\\.0362743860775161\ \(0\)\
\-\ slow\\:\\ 0\\.03622787640115279\ \(0\)\
\-\ primarily\\:\\ 0\\.036054469852734444\ \(0\)\
\-\ subcutaneous\\:\\ 0\\.03580262766159598\ \(0\)\
\-\ suspicion\\:\\ 0\\.03572077482582609\ \(0\)\
\-\ complicated\\:\\ 0\\.03563992634468733\ \(0\)\
\-\ 2004\\:\\ 0\\.035403167872943675\ \(0\)\
\-\ seen\\:\\ 0\\.03539078741630261\ \(0\)\
\-\ also\\:\\ 0\\.03535917251807767\ \(0\)\
\-\ effusions\\:\\ 0\\.03517462235384612\ \(0\)\
\-\ consolidation\\:\\ 0\\.0347400207829889\ \(0\)\
\-\ viral\\:\\ 0\\.03467029453926121\ \(0\)\
\-\ interstitial\\:\\ 0\\.03407389153930827\ \(0\)\
\-\ on\\:\\ 0\\.03405525413765946\ \(0\)\
\-\ uncommon\\:\\ 0\\.03401083777062655\ \(0\)\
\-\ asymmetric\\:\\ 0\\.033825217931325285\ \(0\)\
\-\ association\\:\\ 0\\.033825217931325285\ \(0\)\
\-\ rarely\\:\\ 0\\.033527019147246206\ \(0\)\
\-\ catheter\\:\\ 0\\.03341141848838481\ \(0\)\
\-\ improved\\:\\ 0\\.03335436991950507\ \(0\)\
\-\ home\\:\\ 0\\.03324173352636577\ \(0\)\
\-\ states\\:\\ 0\\.03302207756818367\ \(0\)\
\-\ slight\\:\\ 0\\.03291493588158503\ \(0\)\
\-\ opacity\\:\\ 0\\.032705741532181434\ \(0\)\
\-\ that\\:\\ 0\\.0326222146659559\ \(0\)\
\-\ discharged\\:\\ 0\\.03225800996320035\ \(0\)\
\-\ regions\\:\\ 0\\.03225800996320035\ \(0\)\
\-\ subsequently\\:\\ 0\\.03206838339313115\ \(0\)\
\-\ nodes\\:\\ 0\\.03192966103682448\ \(0\)\
\-\ represent\\:\\ 0\\.0312767442871335\ \(0\)\
\-\ development\\:\\ 0\\.031072732060328772\ \(0\)\
\-\ count\\:\\ 0\\.031032676809044372\ \(0\)\
\-\ smooth\\:\\ 0\\.031032676809044372\ \(0\)\
\-\ frequently\\:\\ 0\\.03095328948071009\ \(0\)\
\-\ atypical\\:\\ 0\\.030835973588585117\ \(0\)\
\-\ continued\\:\\ 0\\.030797327914489706\ \(0\)\
\-\ infectious\\:\\ 0\\.03024329849172727\ \(0\)\
\-\ as\\:\\ 0\\.030199617370401513\ \(0\)\
\-\ tube\\:\\ 0\\.03003410414232367\ \(0\)\
\-\ references\\:\\ 0\\.02996582302823108\ \(0\)\
\-\ there\\:\\ 0\\.029911059181535686\ \(0\)\
\-\ recommended\\:\\ 0\\.029898242245599508\ \(0\)\
\-\ nodules\\:\\ 0\\.029864710017785425\ \(0\)\
\-\ al\\:\\ 0\\.029864710017785425\ \(0\)\
\-\ occurs\\:\\ 0\\.02963464435367136\ \(0\)\
\-\ term\\:\\ 0\\.029475094947152787\ \(0\)\
\-\ presenting\\:\\ 0\\.029443643486267997\ \(0\)\
\-\ et\\:\\ 0\\.029443643486267997\ \(0\)\
\-\ placement\\:\\ 0\\.029350179954022733\ \(0\)\
\-\ lymph\\:\\ 0\\.029227589096114785\ \(0\)\
\-\ typical\\:\\ 0\\.029047876086922067\ \(0\)\
\-\ diagnostic\\:\\ 0\\.028646678445551042\ \(0\)\
\-\ are\\:\\ 0\\.028524692480654194\ \(0\)\
\-\ specific\\:\\ 0\\.02848194315160978\ \(0\)\
\-\ at\\:\\ 0\\.02839375178714918\ \(0\)\
\-\ pleural\\:\\ 0\\.028294817067349425\ \(0\)\
\-\ process\\:\\ 0\\.028190226481722754\ \(0\)\
\-\ result\\:\\ 0\\.028138547247822873\ \(0\)\
\-\ cough\\:\\ 0\\.028061780532370986\ \(0\)\
\-\ course\\:\\ 0\\.027763356615685925\ \(0\)\
\-\ lungs\\:\\ 0\\.02773908745917056\ \(0\)\
\-\ could\\:\\ 0\\.027339627670518243\ \(0\)\
\-\ early\\:\\ 0\\.02709348783243567\ \(0\)\
\-\ grade\\:\\ 0\\.0270279244204005\ \(0\)\
\-\ including\\:\\ 0\\.02689872285836334\ \(0\)\
\-\ required\\:\\ 0\\.026835059865091958\ \(0\)\
\-\ venous\\:\\ 0\\.026835059865091958\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.02668886217245265\ \(0\)\
\-\ obtained\\:\\ 0\\.02658638625710897\ \(0\)\
\-\ status\\:\\ 0\\.026230133630131144\ \(0\)\
\-\ new\\:\\ 0\\.02600290185214946\ \(0\)\
\-\ 30\\:\\ 0\\.02564077399647669\ \(0\)\
\-\ enlarged\\:\\ 0\\.02562317967749167\ \(0\)\
\-\ less\\:\\ 0\\.025570676861496486\ \(0\)\
\-\ thickening\\:\\ 0\\.025570676861496486\ \(0\)\
\-\ first\\:\\ 0\\.025364751710147956\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.025165067685048493\ \(0\)\
\-\ central\\:\\ 0\\.02509982884967627\ \(0\)\
\-\ cancer\\:\\ 0\\.02503522962102621\ \(0\)\
\-\ long\\:\\ 0\\.024923682870446835\ \(0\)\
\-\ positive\\:\\ 0\\.02476753649835487\ \(0\)\
\-\ finding\\:\\ 0\\.024706099516707505\ \(0\)\
\-\ several\\:\\ 0\\.024660394811756227\ \(0\)\
\-\ air\\:\\ 0\\.02458491782901887\ \(0\)\
\-\ should\\:\\ 0\\.02452515262521778\ \(0\)\
\-\ past\\:\\ 0\\.024465924643999007\ \(0\)\
\-\ patient\\:\\ 0\\.02444996698255052\ \(0\)\
\-\ differential\\:\\ 0\\.024421850442577914\ \(0\)\
\-\ onset\\:\\ 0\\.024135324059327785\ \(0\)\
\-\ image\\:\\ 0\\.02403791261291719\ \(0\)\
\-\ during\\:\\ 0\\.023807169848256378\ \(0\)\
\-\ some\\:\\ 0\\.023649024611917827\ \(0\)\
\-\ demonstrated\\:\\ 0\\.023099617475241\ \(0\)\
\-\ for\\:\\ 0\\.02278432568636107\ \(0\)\
\-\ appearance\\:\\ 0\\.022659410571383196\ \(0\)\
\-\ edema\\:\\ 0\\.02241738084452255\ \(0\)\
\-\ been\\:\\ 0\\.021898288240327246\ \(0\)\
\-\ if\\:\\ 0\\.021838658253767157\ \(0\)\
\-\ therapy\\:\\ 0\\.021595850068265466\ \(0\)\
\-\ low\\:\\ 0\\.021567305322345773\ \(0\)\
\-\ common\\:\\ 0\\.021315819178392297\ \(0\)\
\-\ who\\:\\ 0\\.021261213325440217\ \(0\)\
\-\ increased\\:\\ 0\\.02032496188218734\ \(0\)\
\-\ imaging\\:\\ 0\\.019752948560407147\ \(0\)\
\-\ other\\:\\ 0\\.01951924403953202\ \(0\)\
\-\ lower\\:\\ 0\\.019206714167952933\ \(0\)\
\-\ multiple\\:\\ 0\\.018384348003275357\ \(0\)\
\-\ after\\:\\ 0\\.018233800345241576\ \(0\)\
\-\ well\\:\\ 0\\.018199541679444573\ \(0\)\
\-\ within\\:\\ 0\\.01731115727345213\ \(0\)\
\-\ has\\:\\ 0\\.01716839263906003\ \(0\)\
\-\ by\\:\\ 0\\.015961384221400587\ \(0\)\
\-\ from\\:\\ 0\\.014927742228363192\ \(0\)\
\-\ not\\:\\ 0\\.014838234173702012\ \(0\)\
\-\ this\\:\\ 0\\.012915379183005069\ \(0\)\
